n 2013 the Israeli supreme court ruled that the Israeli army would fund GcMAF treatment for a veteran with Hepatitis C who for medical reasons could not receive the standard treatment, and who had previously demonstrated a dramatically reduced HCV viral load in his liver, following privately funded treatment with GcMAF
Efranat, an Israeli company has acquired the patents from Yamamoto and was working to advance his procedures., but later distanced itself from him. They have been conducting clinical tests at the Sheba Medical Center in Israel, to determine toxicity and as a secondary objective to preliminarily explore its effects on cancer.These studies culminated in May 2017 with no results published. According to the company’s website in June 2017, they claim that the results were positive, that they were able to determine non-toxic doses for treatment.